论文部分内容阅读
肿瘤坏死因子TNF-α是迄今为止发现的抗肿瘤作用最强的细胞因子,是所有细胞因子中唯一具有直接杀伤肿瘤细胞作用的因子。国外临床研究显示,肿瘤坏死因子用于不能手术切除的软组织肉瘤的隔离肢端灌流,治疗有效率为70%-90%;用于转移性黑色素瘤的隔离肢端灌流有效率达64%-100%。国外还有尝试将肿瘤坏死因子用于肝癌的隔离灌注,取得了75%的有效率。因此,肿瘤坏死因子的局部给药临床研究肯定了TNF-α对肿瘤治疗的明确疗效。天恩福(注射用重组改构人肿瘤坏死因子)是经过结构改造后的肿瘤坏死因子,相比于野生型肿瘤坏死因子,其抗癌活性提高10倍,毒性下降了5倍。于2004年在中国正式上市,临床主要用于治疗恶性胸腹水及联合化疗治疗晚期非霍奇金淋巴瘤和非小细胞肺癌,特别是治疗恶性胸腹水的疗效较好(国外文献报道肿瘤坏死因子治疗恶性胸腹水的有效率达87%)。为进一
Tumor necrosis factor-α (TNF-α) is by far the most antitumor cytokine found, and is the only cytokine that has the direct effect of killing tumor cells. Foreign clinical studies have shown that the tumor necrosis factor for the treatment of unresectable soft tissue sarcoma isolated acral perfusion, the treatment efficiency was 70% -90%; for the isolation of extremity mesenteric limbal perfusion 64% -100 %. There are also foreign countries trying to tumor necrosis factor for isolated perfusion of liver cancer, achieved a 75% efficiency. Therefore, the clinical study of local administration of tumor necrosis factor affirms the definite effect of TNF-α on cancer therapy. TIENFOR (Recombinant Human Tumor Necrosis Factor for Injection) is a structurally modified tumor necrosis factor that exhibits a 10-fold more potent anticancer activity and a 5-fold less toxicity than wild-type tumor necrosis factor. Was officially launched in China in 2004. It is mainly used in the treatment of malignant pleural and hydrothorax combined with chemotherapy for advanced non-Hodgkin’s lymphoma and non-small cell lung cancer, especially for the treatment of malignant pleural effusion. In foreign countries, tumor necrosis factor Treatment of malignant pleural effusion efficiency of 87%). To enter one